What Happened?
Cambridge, MA-based Spero-Therapeutics Appointed Ankit Mahadevia as Founder and Chief Executive Officer
Date of management change: March 15, 2013
Cambridge, MA-based Spero-Therapeutics Appointed Ankit Mahadevia as Founder and Chief Executive Officer
Spero is a multi-asset, clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts dedicated to identifying, developing and commercializing novel treatments focused on unmet needs of patients with multidrug-resistant (MDR) bacterial infections. Spero`s lead product candidate, SPR994, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Spero also has a platform technology known as its Potentiator Platform that it believes will enable it to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. Spero`s lead product candidates generated from its Potentiator Platform are two intravenous, or IV,-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the hospital setting. Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of pulmonary non-tuberculous mycobacterial infection.
Ankit Mahadevia is Founder and Chief Executive Officer at Spero Therapeutics. Previously, Ankit held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Hanson Barbara, Amato Denise, Kennedy Anita, Small Alex, Fellowes Matt, Freesmeyer Sam, Brien Jan, Street Matthew, Cathey Glen, Negron Diane, Doenges John
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.